eSymposia | Antibodies and Vaccines as Drugs for COVID-19

Jan 13, 2021 ‐ Jan 14, 2021



Sessions

Combating COVID‑19: Identifying a Potential Drug Candidate for Human Testing in 90 Days

Jan 13, 2021 9:00am ‐ Jan 13, 2021 9:15am

Speaker(s):

Antibodies as Drugs for COVID‑19

Jan 13, 2021 9:00am ‐ Jan 13, 2021 11:40am

Co-Chair(s):

Rapid Selection, Characterization and Clinical Development of Fully‑Human Antibodies Against Emerging Infectious Diseases

Jan 13, 2021 9:15am ‐ Jan 13, 2021 9:30am

Speaker(s):

Cross‑Neutralization of SARS‑CoV‑2 by a Human Monoclonal SARS‑CoV Antibody

Jan 13, 2021 9:30am ‐ Jan 13, 2021 9:45am

Speaker(s):

Neutralizing Antibodies—The Hope for a COVID‑19 Cure

Jan 13, 2021 9:45am ‐ Jan 13, 2021 10:00am

Speaker(s):

Coffee Break iconCoffee Break

Preview Available

Coffee Break

Jan 13, 2021 10:00am ‐ Jan 13, 2021 10:25am


Human Neutralizing Antibodies Elicited by SARS‑CoV‑2 Infection

Jan 13, 2021 10:25am ‐ Jan 13, 2021 10:40am

Speaker(s):

When Size Matters: A Broadly Neutralizing Single Domain Antibody to Prevent and Treat COVID 19

Jan 13, 2021 10:40am ‐ Jan 13, 2021 10:55am

Speaker(s):

Highly Potent Anti‑SARS‑CoV‑2 Multivalent DARP in Therapeutic Candidates

Jan 13, 2021 10:55am ‐ Jan 13, 2021 11:10am

Speaker(s):

Therapeutic Effect of Regdanvimab (CT‑P59) in Patients with Mild to Moderate Symptoms of SARS CoV 2 Infection

Jan 13, 2021 11:10am ‐ Jan 13, 2021 11:25am

Speaker(s):
Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
Number of hours attended:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content